Heparin Binding Protein Versus Platelet Count and Mean Platelet Volume Kinetics in the Diagnosis and Prognosis of VAP

Launched by ESRAA HAMDY THABIT RIAD · May 25, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how certain blood markers can help doctors diagnose and understand the prognosis of ventilator-associated pneumonia (VAP) in patients who have been on a ventilator for more than 48 hours. The study will enroll patients who show signs of VAP and classify them into two groups: those who recover and can be taken off the ventilator, and those who do not survive or need to stay on the ventilator for a longer time. The goal is to measure specific blood markers, like heparin-binding protein and platelet counts, to see if they can predict how well a patient might do.

To be eligible for this trial, participants must be between 18 and 70 years old, have been on a ventilator for at least two days, and have clinical signs of VAP. Patients with certain pre-existing conditions or severe blood disorders will not be included. Those who join the trial will have their blood drawn for testing, but the results will be kept separate from their treatment decisions to ensure fairness. This study aims to potentially improve how doctors make decisions about treating patients with VAP.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients \< 18 years old\<70years 2. MV for more than 48 h. 3 . Signs of VAP according to clinical and radiological data , Modified Clinical Pulmonary Infection Score (CPIS) will be calculated for the patients and will be included when CPIS \> 6 . Modified CPIS will be calculated without considering culture results.(12)
• Exclusion Criteria:
• • - . Patients with pre-existing infections or sepsis at ICU admission. 2. Patients with underlying conditions such cancer, chronic liver illnesses, end-stage renal disease, etc. that may impact platelet function or morphology.
• • 3. primary hematological disorders, disseminated intravascular coagulation. 4.severe thrombocytopenia (platelet count ≤ 20x109 L-1) and receiving platelet transfusion.